What Is Tesamorelin? Definition and What Research Reports
Tesamorelin is a synthetic analogue of human growth hormone-releasing factor (GRF/GHRH) that stimulates the pituitary to release growth hormone, which in turn raises circulating IGF-1. It was developed and studied mainly in people living with HIV who had excess visceral abdominal fat, and reviews describe a once-daily subcutaneous formulation. Published trials and reviews have reported changes in visceral adipose tissue, liver enzymes, inflammatory markers and fat quality, along with tolerability findings. This page defines the term and summarises literature only.
Plain-language definition
Tesamorelin is a laboratory-made version of a natural hormone signal that the brain uses to tell the pituitary gland to release growth hormone. Instead of supplying growth hormone directly, it acts one step earlier in the chain: it mimics growth hormone-releasing factor (also called GHRH or GRF), so the body's own pituitary produces the hormone in its usual pulsing pattern. Because growth hormone drives production of insulin-like growth factor 1 (IGF-1) in the liver, measurements of IGF-1 are commonly used in studies as a marker that the signal reached its target. Tesamorelin was developed and tested chiefly in adults living with HIV who had accumulated excess fat deep inside the abdomen, a pattern often called HIV-associated lipodystrophy.
What tesamorelin is in biochemical and regulatory terms
In structural terms, tesamorelin is a synthetic analogue of the 44-amino-acid human growth hormone-releasing factor, GRF(1-44), modified at the N-terminus to slow enzymatic breakdown and extend its activity relative to the unmodified peptide. Early drug evaluations characterised it as a synthetic human growth hormone-releasing factor developed for metabolic indications, describing its mechanism as stimulation of endogenous growth hormone secretion rather than exogenous growth hormone replacement (PMID 17086939). A later investigational-drugs review reiterated this classification and summarised the clinical programme in HIV-associated fat accumulation (PMID 19243281).
In regulatory terms, tesamorelin is the active ingredient in a prescription product approved in the United States for the reduction of excess visceral abdominal fat in adults with HIV-associated lipodystrophy. Reviews published after approval described the formulation studied in the pivotal programme as a 2 mg once-daily subcutaneous injection (PMID 21668043, PMID 22298602). Material sold or supplied under research-use-only (RUO) labelling is not an approved medicine and is not intended for human administration; that distinction is a labelling and regulatory fact, not a statement about any individual's situation.
How the term is used in peptide research
Within the published literature, "tesamorelin" is used narrowly and consistently: it names a specific GRF analogue with a defined structure and a defined clinical development history. Researchers use the term in several recurring contexts:
- As a pharmacological probe of the GH/IGF-1 axis. Because it works through the pituitary, it is used to study what happens when endogenous growth hormone secretion is amplified rather than replaced.
- As an intervention in body-composition studies. Trials in people with HIV and excess abdominal fat measured visceral adipose tissue as the primary outcome (PMID 21668043).
- As a tool for mechanistic work. One analysis applied targeted proteomic and transcriptomic methods to delineate tesamorelin response pathways in HIV-associated non-alcoholic fatty liver disease (PMID 34006921).
- As a modelling subject. A population pharmacokinetic and pharmacodynamic analysis characterised drug exposure and IGF-1 response across HIV-infected patients and healthy subjects (PMID 25895899).
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhere the term is misused
Outside the peer-reviewed literature, the word drifts. Common misuses include:
- Treating it as a growth hormone. Tesamorelin is not somatropin. The evaluations describing it classify it as a releasing-factor analogue that acts upstream of growth hormone secretion (PMID 17086939).
- Conflating it with ghrelin-receptor secretagogues. Compounds such as ipamorelin, GHRP-2 and GHRP-6 act at a different receptor. Grouping them all as "GH peptides" obscures distinct mechanisms.
- Treating it as interchangeable with other GRF analogues. Sermorelin (GRF 1-29) and CJC-1295 are separate molecules with separate literatures; findings reported for tesamorelin do not transfer to them.
- Generalising beyond the studied population. Nearly all of the published efficacy work was conducted in adults living with HIV and abdominal fat accumulation (PMID 38905488). Describing it as a general "fat-loss peptide" extends the evidence past where it was collected.
- Marketing language. Phrases such as body-recomposition or anti-ageing claims do not appear as validated outcomes in the cited trials.
Related terms
| Term | Relationship to tesamorelin |
|---|---|
| GHRH / GRF | The natural hypothalamic hormone that tesamorelin was designed to mimic. |
| Growth hormone (somatropin) | The downstream hormone released by the pituitary; supplied directly in replacement therapy, not by tesamorelin. |
| IGF-1 | Liver-derived mediator used in studies as a pharmacodynamic marker of GH axis activation (PMID 25895899). |
| Visceral adipose tissue (VAT) | The imaging-measured fat depot that served as the primary endpoint in the pivotal programme (PMID 21668043). |
| HIV-associated lipodystrophy | The clinical setting in which tesamorelin was developed and reviewed (PMID 22298602). |
| NAFLD | Liver condition examined in mechanistic and enzyme-focused analyses (PMID 34006921). |
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appWhat the published literature reports
Body composition and visceral fat
Reviews of the clinical programme summarised trials in adults with HIV-associated lipodystrophy in which tesamorelin was studied against placebo, with reductions in visceral adipose tissue reported as the central efficacy finding (PMID 21668043). A pharmacotherapy review published the following year reached similar conclusions when appraising the analogue for that indication (PMID 22298602). A later analysis reported that tesamorelin improved measures of fat quality independent of changes in fat quantity, indicating that quantity-only endpoints did not capture everything the researchers observed (PMID 33756511).
Liver and metabolic markers
In an analysis of participants with HIV, visceral fat reduction with tesamorelin was reported to be associated with improved liver enzymes (PMID 28832410). A separate mechanistic study used targeted proteomic and transcriptomic profiling to delineate the pathways associated with tesamorelin response in HIV-associated NAFLD (PMID 34006921). Researchers have also examined inflammatory markers in HIV patients with excess abdominal fat and their relationship with visceral adipose reduction (PMID 21516030).
Cognition and physical function
A 2025 report in The Journal of Infectious Diseases examined the effects of tesamorelin on neurocognitive impairment in persons with HIV and abdominal obesity, extending investigation beyond metabolic endpoints (PMID 39813152). A published trial protocol, TRIUMPH, described a study designed to evaluate tesamorelin as an adjunct to exercise for improving physical function in people with HIV; as a protocol, it set out methods rather than results (PMID 42419889).
Pharmacokinetics
A population pharmacokinetic and pharmacodynamic analysis modelled tesamorelin exposure and the IGF-1 response in both HIV-infected patients and healthy subjects, providing the quantitative framework used to describe the compound's behaviour after subcutaneous administration (PMID 25895899).
Safety and Tolerability: What Studies Report
Review articles covering the clinical programme discussed tolerability alongside efficacy, noting injection-site reactions among the adverse events recorded and highlighting monitoring of glucose parameters and IGF-1 as considerations raised during development (PMID 22298602, PMID 21668043). A 2024 study assessed efficacy and safety in people with HIV receiving integrase inhibitor-based regimens, a contemporary antiretroviral context that differed from the era of the original trials (PMID 38905488). Earlier evaluations also flagged that, as a stimulator of the GH/IGF-1 axis, the analogue required attention to metabolic monitoring during study (PMID 19243281). Adverse-event profiles described in these publications apply to the studied populations and study conditions only.
Want the full course? Every compound, evidence-graded and cited, inside PeptideU.
Start learning freeHow to read this entry
A glossary definition describes what a term means and where it came from; it does not indicate suitability for any person. The evidence summarised above was generated in defined clinical populations, under medical supervision, with protocol-specified monitoring. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical or health decision.
References
- Drug evaluation: tesamorelin, a synthetic human growth hormone releasing factor (Current Opinion in Investigational Drugs, 2006)
- Tesamorelin, a human growth hormone releasing factor analogue (Expert Opinion on Investigational Drugs, 2009)
- Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction (AIDS, 2011)
- Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy (Drugs, 2011)
- Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy (The Annals of Pharmacotherapy, 2012)
- Population pharmacokinetic and pharmacodynamic analysis of tesamorelin in HIV-infected patients and healthy subjects (Journal of Pharmacokinetics and Pharmacodynamics, 2015)
- Visceral fat reduction with tesamorelin is associated with improved liver enzymes in HIV (AIDS, 2017)
- Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach (Scientific Reports, 2021)
- Tesamorelin improves fat quality independent of changes in fat quantity (AIDS, 2021)
- Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors (AIDS, 2024)
- Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity (The Journal of Infectious Diseases, 2025)
- Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol (BMJ Open, 2026)
Frequently asked questions
What does the word "tesamorelin" mean?▾
Tesamorelin is the international non-proprietary name for a synthetic analogue of human growth hormone-releasing factor, GRF(1-44), modified to resist rapid enzymatic breakdown. Early drug evaluations described it as a synthetic human growth hormone releasing factor that stimulates the pituitary to secrete growth hormone rather than supplying growth hormone itself (PMID 17086939, PMID 19243281). The name carries no dosing or usage meaning.
Is tesamorelin the same as growth hormone?▾
No. Reviews classify tesamorelin as a releasing-factor analogue that acts upstream of the pituitary, prompting the body's own growth hormone secretion, whereas somatropin supplies growth hormone directly (PMID 17086939). Because growth hormone drives IGF-1 production, researchers used IGF-1 as a pharmacodynamic marker when modelling tesamorelin exposure and response in patients and healthy subjects (PMID 25895899).
Which population was tesamorelin studied in?▾
The published efficacy literature centres on adults living with HIV who had excess visceral abdominal fat, often described as HIV-associated lipodystrophy. Reviews summarised this development programme and its visceral adipose tissue endpoints (PMID 21668043, PMID 22298602). A 2024 study extended the assessment to people with HIV receiving integrase inhibitor-based antiretroviral regimens (PMID 38905488).
What outcomes have researchers measured besides visceral fat?▾
Published work has looked beyond fat quantity. One analysis reported that visceral fat reduction was associated with improved liver enzymes (PMID 28832410), another reported improvements in fat quality independent of changes in fat quantity (PMID 33756511), and researchers also examined inflammatory markers in relation to visceral adipose reduction (PMID 21516030). Neurocognitive endpoints were examined separately (PMID 39813152).
How is the term commonly misused?▾
It is often grouped with ghrelin-receptor secretagogues such as ipamorelin or GHRP-6, or treated as interchangeable with sermorelin and CJC-1295, though these act differently and have separate literatures. It is also described as a general fat-loss compound, which extends beyond the HIV populations in which the trials were conducted (PMID 21668043, PMID 38905488).
What do studies report about tolerability?▾
Review articles discussed injection-site reactions among recorded adverse events and highlighted monitoring of glucose parameters and IGF-1 during the development programme (PMID 22298602, PMID 21668043). An earlier evaluation noted that stimulating the GH/IGF-1 axis required metabolic monitoring in study settings (PMID 19243281). These findings describe supervised trial populations, not general use.
Is research on tesamorelin still ongoing?▾
Yes. A published protocol described the TRIUMPH trial, designed to evaluate tesamorelin as an adjunct to exercise for improving physical function in people with HIV; as a protocol it reported methods rather than results (PMID 42419889). Mechanistic work has also used proteomic and transcriptomic profiling to map response pathways in HIV-associated NAFLD (PMID 34006921).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.